Literature DB >> 114390

Human plasma prekallikrein: a rapid high-yield method for purification.

C F Scott, C Y Liu, R W Colman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 114390     DOI: 10.1111/j.1432-1033.1979.tb02035.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


× No keyword cloud information.
  12 in total

1.  Kinetics of inhibition of platelet calpain II by human kininogens.

Authors:  H N Bradford; A H Schmaier; R W Colman
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

2.  Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma.

Authors:  C F Scott; R W Colman
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

3.  Purified human plasma kallikrein aggregates human blood neutrophils.

Authors:  M Schapira; E Despland; C F Scott; L A Boxer; R W Colman
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

4.  Human plasma kallikrein. A rapid purification method with high yield.

Authors:  H Nagase; A J Barrett
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

5.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

6.  Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.

Authors:  A de Agostini; M Schapira; Y T Wachtfogel; R W Colman; S Carrel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

7.  Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor.

Authors:  C F Scott; L D Silver; M Schapira; R W Colman
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

8.  Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.

Authors:  M Schapira; C F Scott; R W Colman
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

9.  Endothelial cells produce a substance that inhibits contact activation of coagulation by blocking the activation of Hageman factor.

Authors:  J Kleniewski; V H Donaldson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

10.  Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf.

Authors:  C F Scott; R W Carrell; C B Glaser; F Kueppers; J H Lewis; R W Colman
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.